Alliance for Integrity and Reform of 340B

08/24/2026

Lack of transparency in the program is enabling duplicate discounts and undermining its mission to help patients. In a Washington Reporter opinion, Pioneer Institute for Public Policy Research Bill Smith explains how the Health Resources and Services Administration (HRSA) revised rebate model could close loopholes:

Most of us know a duplicate discount when we see one, whether that’s getting paid for a missing package by both the delivery service and the seller, or…

08/04/2026

🎉 Health Resources and Services Administration (HRSA)’s 340B Rebate Pilot Program is an important step to bring much-needed transparency to the program & strengthen program integrity.

08/03/2026

💰 purchases topped $100 billion in 2025, a nearly 23% increase from 2024. What began as a program to help patients has become a profit center for large hospitals. Congress must rein in program abuse and end the . Read more from AIR340B member Citizens Against Government Waste:

Congress should deliver much-needed reforms to the 340B program, which would save taxpayers money and put an end to the abuse of 340B.

07/27/2026

🗺️ What’s the story in your state? Across the nation, large, tax-exempt hospitals are exploiting the 340B program for profit while patients, taxpayers and employers are left to foot the bill. Explore the new 2026 AIR340B interactive map to uncover what’s happening in your state and why greater transparency and accountability is needed 🔍 https://340breform.org/340b-hospitals/

07/24/2026

Former CBO director Dan Crippen highlights how the cost of the program falls on employees, employers and taxpayers through increased federal spending and higher health care costs. When will enough be enough? Read more in Washington Examiner:

More than 2,600 hospitals now participate in the 340B program, up from around 50 when it first began over three decades ago.

07/21/2026

Large, hospitals buy prescriptions at steep discounts and pocket the difference. That very practice minimizes competition and increases consolidation while patients and taxpayers are left paying more. Pacific Research Institute Sally Pipes urges Congress to rein in abuse and bring real transparency to 340B. Read more in Detroit News:

Lawmakers are challenging hospital CEOs over rising costs as consolidation and federal programs drive up patient bills.

07/14/2026

🚨The program is at a crossroads. At , experts highlighted growing concerns about the program's rapid expansion, lack of transparency and whether patients are truly benefiting. Patients deserve transparency and reforms that put them first. See more from AIR340B member I am Biotech:

Experts discussed the 340B program and the need for patient-focused reforms at the 2026 BIO International Convention.

07/10/2026

“340B hospitals pursue aggressive medical debt collection practices at higher rates than their non-340B counterparts.” When will enough be enough? The program was put in place to help patients, yet hospitals participating in aggressive collection practices that hurt the patients the program was intended to serve. Transparency and accountability can no longer wait. Read more from National Consumers League in KFF Health News:

KFF Health News gives readers a chance to comment on a recent batch of stories.

07/07/2026

For too long, the federal 340B program has lacked the transparency and accountability it needs, allowing tax-exempt hospitals to mark up medicines and drive up health care costs for Americans. New legislation from the House Ways & Means Committee could change that by establishing new reporting requirements for tax-exempt hospitals. It's a commonsense step to hold hospitals accountable and help ensure sure 340B benefit patients.

07/03/2026

“While discussion around how this program has become a cash cow for corporations has been bubbling for years, recent court decisions should be a wake-up call for Congress to more closely examine its effect on patients and taxpayers.” Read a InsideSources opinion from Pioneer Institute for Public Policy Research Bill Smith on why Congress must address the :

A panel of judges from a federal appeals court recently overturned a West Virginia law requiring pharmaceutical innovators to sell discounted medicines to